Navigation Links
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Date:11/6/2008

- Voreloxin Demonstrates Promising Clinical Activity in Patients with

Difficult-to-Treat Cancers -

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented from Phase 1 and Phase 1b/2 studies in patients with acute myeloid leukemia (AML) showed that preliminary clinical responses were observed in the relapsed/refractory AML population and the data supports further clinical development for voreloxin both as a single agent and in combination with cytarabine. Preliminary efficacy results previously presented from an ongoing Phase 2 trial demonstrate single agent activity of voreloxin in advanced platinum-resistant ovarian cancer and that the drug is generally well tolerated in this difficult-to-treat patient population.

"We believe that voreloxin has the potential to change the standard of care in AML and platinum-resistant ovarian cancer and look forward to reporting updated results of our AML trials at ASH," said Daniel Swisher, Chief Executive Officer, Sunesis Pharmaceuticals. "Our goal is to advance voreloxin into a pivotal trial in AML by the end of 2009."

Phase 1 and 1b/2 Studies of Voreloxin in AML

Data presented from a completed Phase 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that single agent voreloxin was generally well tolerated, with the most frequently observed dose limited toxicity (DLT) being reversible grade 3/4 oral mucositis. The researchers concluded that single agent a
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ANGELES , FARUM, Denmark and ... On July 31, 2015 the US Food and ... the treatment of Major Depressive Disorder in adult patients who ... in the current episode. TMS is a non-invasive technique for ... in patients suffering from Major Depressive Disorder. The procedure has ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic Acids, ... by Region ( North America , ... of the World) - Global Trends and Forecast to 2020", ... at USD 4.62 Billion in 2014 and is projected to ... 7.4% from 2015 to 2020. Browse 77 ...
(Date:8/28/2015)... , August 28, 2015 ... to reach USD 49.12 billion by 2020, growing at ... to a new report by Grand View Research, Inc. ... CAGR of 49.7% from 2014 to 2020. ... aging population along with rising incidences of chronic diseases ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Pro X . Each preset contains 15 seconds of unique footage that users can ... that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number of ... transitioned management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department ... qualified for the position they are applying for, they are unable to pass the ... are considering altering drug testing policies in order to be able to hire long-term, ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... your father when you are born may affect your ... risk of schizophrenia associated with advanced paternal age, particularly ... distorts the way a person thinks, acts, expresses emotions, ... life-long disease that cannot be cured, but usually can ...
... born without a thymus - an essential immune system component ... tissue normally discarded during cardiac operations on other infants, researchers ... in the United States each year without a thymus gland, ... system. ,The thymus is the organ that programs the ...
... you break out. There are a lot of anecdotal stories ... looked at this, Dr. Alexa B. Kimball, from Stanford University ... goal of debunking this myth," she added. ,"There are a ... causes stress," Kimball noted. But when she and her associates ...
... people who eat fish at least once a week may ... study suggests. The study adds to the evidence that diet ... that affects 4 million Americans. ,Researchers found that people ... a 60 percent lower risk of Alzheimer's than those who ...
... shows death risks among homeless people are dramatically different ... followed more than 750 homeless people for 10 years. ... and an interview group. Researchers studied the information provided ... the interview group were asked questions about their upbringing, ...
... drug fondaparinux (Arixta) nearly halves the risk of ... in people hospitalized with congestive heart failure, chronic ... risk of these conditions, claims a new study. ... less likely to suffer venous thromboembolism (a condition ...
Cached Medicine News:
... This remarkable anti-reflux valve ... plastic housing which prevents the ... closed when in sitting or ... virtually self-cleaning and interference free ...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
... aggregation and ristocetin cofactor testing, couples ... of Windows-based software for unsurpassed testing ... modules can be run on one ... can configure your analyzers to suite ...
Medicine Products: